NCT01838538

Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: —

Summary

To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab

Conditions

• Ovarian Cancer With Malignant Ascites

Interventions

Type	Name	Description
DRUG	Bevacizumab
DRUG	TC:paclitaxel + carboplatin

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-06-01
• First posted: 2013-04-24
• Last updated: 2013-04-24

Locations

1 site across 1 country: China